CRISPR Therapeutics AG’s recent filing unveils that its Director Treco Douglas A acquired Company’s shares for reported $1.14 million on Aug 06 ’25. In the deal valued at $57.03 per share,20,000 shares were bought. As a result of this transaction, Treco Douglas A now holds 22,000 shares worth roughly $1.21 million.
Then, George Simeon bought 989,812 shares, generating $51,499,918 in total proceeds. Upon buying the shares at $52.03, the Director now owns 1,730,179 shares.
Before that, Patel Naimish sold 3,932 shares. CRISPR Therapeutics AG shares valued at $141,316 were divested by the Chief Medical Officer at a price of $35.94 per share. As a result of the transaction, Patel Naimish now holds 6,068 shares, worth roughly $0.33 million.
Evercore ISI upgraded its CRISPR Therapeutics AG [CRSP] rating to an Outperform from a an In-line in a research note published on February 14, 2025; the price target was increased to $99 from $60. A number of analysts have revised their coverage, including TD Cowen’s analysts, who increased its forecast for the stock in mid February from “a Sell” to “a Hold”. H.C. Wainwright began covering CRSP with “Buy” recommendation on February 03, 2025. Needham maintained its rating on August 06, 2024. It rated CRSP as “a Buy”.
Price Performance Review of CRSP
On Friday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock fall -1.72% to $55.0. Over the last five days, the stock has lost -1.94%. CRISPR Therapeutics AG shares have risen nearly 11.49% since the year began. Nevertheless, the stocks have risen 39.74% over the past one year.
How much short interest is there in CRISPR Therapeutics AG?
A steep rise in short interest was recorded in CRISPR Therapeutics AG stocks on 2025-07-15, growing by 3.89 million shares to a total of 25.3 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 21.41 million shares. There was a rise of 15.36%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 02, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $90 price target.
